{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:10:25Z","timestamp":1790079025488,"version":"4.0.1"},"reference-count":39,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy Carol Davila"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Objectives: Longitudinal visual and imaging outcomes after intravitreal methotrexate (MTX) for vitreoretinal lymphoma (VRL), and baseline factors associated with remission, remain poorly defined. We evaluated the 12-month efficacy and safety of a reduced-intensity induction regimen followed by response-guided continuation therapy. Methods: Seventeen consecutive patients with VRL confirmed by vitreous cytology and flow cytometry received intravitreal MTX (400 \u03bcg\/0.1 mL) at two centers in Bucharest, Romania, between 2018 and 2023. Visual acuity (VA), vitritis and optical coherence tomography (OCT) findings were assessed at baseline and at 1, 3, 6 and 12 months (Friedman and Cochran\u2019s Q tests). Results: Mean VA improved from 1.22 \u00b1 0.70 to 0.74 \u00b1 0.63 logMAR (\u03c72 = 30.82, p &lt; 0.001; Kendall\u2019s W = 0.45), with statistically significant improvement from month 6. At the scheduled 12-month assessment, vitritis and retinal infiltrates had resolved (both unadjusted p &lt; 0.001). Sub-RPE lesions and outer retinal hyperreflectivity decreased (both unadjusted p = 0.031), but these comparisons did not meet the Bonferroni-adjusted significance threshold. Outer retinal disorganization and foveal involvement did not change significantly. Fourteen patients (82.4%) achieved complete ocular remission (median, 6 months); three (17.6%) relapsed and regained disease control after retreatment. Keratopathy was the most frequent adverse event (41.2%); no severe complications occurred. Conclusions: This regimen was associated with a high ocular remission rate, progressive visual improvement and a manageable safety profile. Because all 10 patients with central nervous system lymphoma also received systemic therapy and\/or radiotherapy, ocular outcomes cannot be attributed solely to intravitreal MTX.<\/jats:p>","DOI":"10.3390\/jcm15187323","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:09:35Z","timestamp":1790075375000},"page":"7323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Response-Adapted Intravitreal Methotrexate Therapy for Vitreoretinal Lymphoma: A Two-Center Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Mihai-Luca","family":"Cioboat\u0103","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-4501","authenticated-orcid":false,"given":"Ioana","family":"Tofolean","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"},{"name":"Retina Clinic, 014142 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-2185","authenticated-orcid":false,"given":"Suher","family":"Abduraman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Radu","family":"Burcea","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3748-8726","authenticated-orcid":false,"given":"Maria-Alexandra","family":"Chiotan-C\u0103lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu-Alexandru","family":"Chiotan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"National Institute of Pneumophthisiology \u201cMarius Nasta\u201d, 050159 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Dana-Margareta-Cornelia","family":"D\u0103sc\u0103lescu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Miruna","family":"Cioboat\u0103","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Ali R\u0131za Cenk","family":"\u00c7elebi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Istanbul Medipol University, 34196 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Florian","family":"Balt\u0103","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Carol Davila University of Medicine & Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Ophthalmology, Clinical Institute of Ophthalmological Emergencies \u201cProf. Dr. Mircea Olteanu\u201d, 010464 Bucharest, Romania"},{"name":"Retina Clinic, 014142 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.83.4.448","article-title":"Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma","volume":"83","author":"Vancs","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0161-6420(02)01125-9","article-title":"Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement","volume":"109","author":"Smith","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_3","first-page":"204","article-title":"Diagnostic and therapeutic challenges in primary vitreoretinal lymphoma: A practical clinical approach","volume":"70","author":"Tofolean","year":"2026","journal-title":"Rom. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","article-title":"The diagnosis and treatment of primary vitreoretinal lymphoma: A review","volume":"4","author":"Pulido","year":"2018","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sobolewska, B., Chee, S.P., Zaguia, F., Goldstein, D.A., Smith, J.R., Fend, F., Mochizuki, M., and Zierhut, M. (2021). Vitreoretinal lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13163921"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/bjo.2007.127928","article-title":"Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience","volume":"92","author":"Frenkel","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41433-021-01657-0","article-title":"A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma","volume":"36","author":"Zhou","year":"2022","journal-title":"Eye"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhou, X., Zhou, X., Shi, H., Lai, J., Wang, Q., Li, Y., Chen, K., Li, Q., Zhou, Q., and Cao, X. (2020). Reduced frequency of intravitreal methotrexate injection lowers the risk of keratopathy in vitreoretinal lymphoma patients. BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-01464-3"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40942-021-00346-0","article-title":"Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma","volume":"7","author":"Anthony","year":"2021","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1038\/s41598-023-31414-0","article-title":"Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: A single tertiary center experience","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jiang, T., Gu, J., Liu, S., and Chang, Q. (2022). Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02604-7"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40942-022-00405-0","article-title":"Multimodal diagnostic imaging in primary vitreoretinal lymphoma","volume":"8","author":"Xu","year":"2022","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: A report from an International PCNSL Collaborative Group symposium","volume":"16","author":"Chan","year":"2011","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/bjh.17451","article-title":"Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma: 20 years of experience","volume":"194","author":"Frenkel","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjophthalmol-2017-311574","article-title":"Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse","volume":"102","author":"Klimova","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ajo.2008.12.025","article-title":"Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma","volume":"147","author":"Fardeau","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/bjophthalmol-2017-311612","article-title":"Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma","volume":"102","author":"Barry","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/10428199609054837","article-title":"A single-center study of 11 patients with intraocular lymphoma","volume":"23","author":"Soussain","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1002\/cam4.5609","article-title":"Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma","volume":"12","author":"Cheng","year":"2023","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10384-023-00997-6","article-title":"Diagnosis and management of vitreoretinal lymphoma: Present and future treatment perspectives","volume":"67","author":"Kaburaki","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Deckert","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_22","unstructured":"International Vitreoretinal B-Cell Lymphoma Registry Investigator Group (2024). Presentation, diagnostic testing and initial treatment of vitreoretinal lymphoma. Ophthalmol. Retin., 8, 72\u201380."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archopht.1997.01100160322009","article-title":"Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma","volume":"115","author":"Fishburne","year":"1997","journal-title":"Arch. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s00277-025-06414-x","article-title":"Relapses and outcomes of systemic chemo-free therapies combined with intravitreous methotrexate in isolated primary vitreoretinal lymphoma: An analysis based on two prospective cohort studies","volume":"104","author":"Chen","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/eye.2012.250","article-title":"Intraocular lymphoma: A clinical perspective","volume":"27","author":"Davis","year":"2013","journal-title":"Eye"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.1.3.1","article-title":"Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma","volume":"1","author":"Hashida","year":"2012","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0161-6420(99)90341-X","article-title":"Intraocular-central nervous system lymphoma: Clinical features, diagnosis, and outcomes","volume":"106","author":"Akpek","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_28","first-page":"1","article-title":"Intraocular lymphoma: A review","volume":"20","author":"Karimi","year":"2025","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","article-title":"Use of intravitreal rituximab for treatment of vitreoretinal lymphoma","volume":"98","author":"Larkin","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.eye.6702804","article-title":"Intraocular use of rituximab","volume":"21","author":"Kitzmann","year":"2007","journal-title":"Eye"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, X., Zou, D., Yin, J., Zhang, L., Wang, X., Jia, C., Wang, W., Zhao, D., and Zhou, D. (2021). Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.701507"},{"key":"ref_32","first-page":"93","article-title":"Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma","volume":"15","author":"Chan","year":"2013","journal-title":"Discov. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","article-title":"Primary intraocular lymphoma","volume":"59","author":"Sagoo","year":"2014","journal-title":"Surv. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/11206721231211931","article-title":"A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma","volume":"34","author":"Menean","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00233","DOI":"10.1097\/BS9.0000000000000233","article-title":"Primary vitreoretinal lymphoma: Diagnosis, treatment, and prognosis\u2014A review of current knowledge and future directions","volume":"7","author":"Wang","year":"2025","journal-title":"Blood Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09273948.2021.1878233","article-title":"Consensus recommendations for the diagnosis of vitreoretinal lymphoma","volume":"29","author":"Carbonell","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamaophthalmol.2018.2887","article-title":"Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction","volume":"136","author":"Leguit","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","article-title":"A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas","volume":"107","author":"Wang","year":"2022","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gu, J., Jiang, T., Liu, S., Ping, B., Li, R., Chen, W., Wang, L., Huang, X., Xu, G., and Chang, Q. (2022). Cell-free DNA sequencing of intraocular fluid as liquid biopsy in the diagnosis of vitreoretinal lymphoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.932674"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:35:30Z","timestamp":1790076930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":39,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187323"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187323","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}